Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study suggests that using nanostructured lipid carriers may improve the targeting of 17-α-estradiol in treating alopecia by improving skin penetration and stability.

This study describes a planned multicenter randomized controlled trial to assess the safety, tolerability, and pharmacokinetics of subdermal gestrinone pellets in patients with deep infiltrative endometriosis-related pelvic pain, but it does not report any findings yet.

This article reviews hair loss associated with oral contraceptive use and suggests that while diffuse effluvium is usually harmless, androgenetic alopecia caused by certain contraceptive types requires a change in medication; no new clinical results are reported.

This review discusses contraceptive options for adolescent girls, highlighting potential recommendations and contraindications, and reports no new clinical findings.

This article reviews the contraceptive agent Depo-Provera, discussing its effectiveness, potential side effects, and safety concerns, but reports no new clinical results.

This article reviews various updates in dermatology, including drug safety alerts and treatment options, and reports no new clinical results.

This study found that GnRH-a treatment or orchiectomy, which required significantly lower doses of oral estradiol valerate, were more effective than anti-androgens like spironolactone and finasteride in achieving target hormone levels in transgender females in India.

In this study, 12 months of cyproterone acetate and ethinyl oestradiol treatment significantly reduced hair growth rate and certain hormone levels in hirsute women, though hair density and prolactin levels remained unchanged.

This study found that medroxyprogesterone acetate and ethinyl estradiol with drospirenone were the most frequently prescribed medications for PCOS, with some patients experiencing drug changes or discontinuation due to side effects or therapeutic failure.

This study found that combined hormonal contraceptives containing ethenyl estradiol and cyproterone acetate improved acne, hirsutism, menstrual irregularity, and dysmenorrhea in patients with polycystic ovarian syndrome, with most participants showing significant symptom improvement after 6 to 12 months.

This study found that oral contraceptive pills containing cyproterone acetate and drospirenone were more effective at reducing hirsutism in women with PCOS than those containing levonorgestrel over a 6-month period.

This article reviews the potential neuroprotective effects of 17α‐estradiol in neurodegenerative diseases and highlights its possibly lower toxicity compared to more feminizing hormones, but it reports no new clinical findings.

This study found that elagolix treatment did not normalize the ovulatory cycle in patients with polycystic ovarian syndrome.

This review discusses the complex dermatological effects of oral contraceptives, including both hormonal benefits and potential toxicities, but reports no new clinical results.

This study found that both spironolactone with Ovysmen and cyproterone acetate with ethinyloestradiol significantly reduced hair growth in hirsute women, with no difference in effect between treatments.

This article reviews the role of androgens and oral contraceptives in acne pathogenesis and management but presents no new clinical results.

This review discusses treatments for female acne, highlighting the effectiveness of low-dose oral contraceptives and noting their similar side effects to placebo; it reports no new clinical results.

This article reviews clinical and treatment aspects of hyperandrogenism in women, emphasizing the roles of diagnostic practices, combined oral contraceptives, and cyproterone acetate, but introduces no new findings.

This article reviews various side effects and concerns related to oral contraceptives, including potential vascular complications and elevated plasma cortisol levels, but reports no new clinical results.

This review summarizes recent developments in oral contraceptive pills and other contraceptive methods, highlighting advances in formulations and delivery systems to improve efficacy and user compliance.

This study found that the oral contraceptive containing drospirenone (EE/DRSP) was as effective as EE/CPA in reducing acne lesions, sebum production, and hair growth in women with acne.

Estetrol may help prevent hair loss and support hair growth in women.

This study compared letrozole and clomiphene citrate for ovulation induction in women with polycystic ovary syndrome and found that while clomiphene led to more follicles, monofollicular development and endometrial thickness were higher with letrozole, and pregnancy rates did not significantly differ between the two treatments.

This study found that free testosterone levels were 29% higher with the levonorgestrel implant than with the DMPA injection, which may impact sexual function, mood, and side effects like acne.

This letter highlights that levonorgestrel intrauterine devices may lead to fewer systemic side effects, like acne, compared to its oral administration due to lower systemic levels of progestogens.

This article suggests using oral contraceptives with antiandrogenic properties for women with virilization symptoms like acne and advises higher doses of antiandrogens for severe acne, androgenic alopecia, or idiopathic hirsutism.

This article discusses the impact of estrogens on skin aging, highlighting the potential benefits and unresolved effectiveness of alternatives like phytoestrogens and selective estrogen receptor modulators; it reports no new clinical results.

This study found that estradiol transdermal patches helped many MTF patients achieve target estrogen levels, especially those who could not reach these levels with oral therapy and those at higher thrombotic risk.

This review discusses the role of contraceptives in dermatology, particularly for acne treatment and managing patients on teratogens, but reports no new clinical results.